Cargando…
Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia
Autores principales: | Karlsson, C, Dahl, H, Lundin, J, Rossmann, E, Brytting, M, Mellstedt, H, Linde, A, Österborg, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255266/ https://www.ncbi.nlm.nih.gov/pubmed/22829166 http://dx.doi.org/10.1038/bcj.2011.20 |
Ejemplares similares
-
Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
por: Winqvist, Maria, et al.
Publicado: (2016) -
Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Hwang, William Y. K., et al.
Publicado: (2009) -
Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
por: Montillo, Marco, et al.
Publicado: (2008) -
Alemtuzumab in chronic lymphocytic leukemia
por: Fraser, G., et al.
Publicado: (2007) -
First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab
por: Schweighofer, Carmen Diana, et al.
Publicado: (2010)